Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)

To explore the effects of immunotherapy in the International Society of Paediatric Oncology Europe Neuroblastoma Group SIOPEN high-risk neuroblastoma 1 trial (HR-NBL1 trial), two cohorts were studied: one prior to and one after the introduction of dinutuximab beta. All patients received standard ind...

Descripción completa

Detalles Bibliográficos
Autores principales: Ladenstein, Ruth, Pötschger, Ulrike, Valteau-Couanet, Dominique, Luksch, Roberto, Castel, Victoria, Ash, Shifra, Laureys, Geneviève, Brock, Penelope, Michon, Jean Marie, Owens, Cormac, Trahair, Toby, Chi Fung Chan, Godfrey, Ruud, Ellen, Schroeder, Henrik, Beck-Popovic, Maja, Schreier, Guenter, Loibner, Hans, Ambros, Peter, Holmes, Keith, Castellani, Maria Rita, Gaze, Mark N., Garaventa, Alberto, Pearson, Andrew D.J., Lode, Holger N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072500/
https://www.ncbi.nlm.nih.gov/pubmed/32013055
http://dx.doi.org/10.3390/cancers12020309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072500/
https://www.ncbi.nlm.nih.gov/pubmed/32013055
http://dx.doi.org/10.3390/cancers12020309

Ejemplares similares